Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC | OncLive
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.
onclive.com